A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2001-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide
in patients with hormone-refractory prostate cancer.
An important aspect of this study is to characterize the pharmacokinetics of thalidomide, as
well as make correlations between the degree of angiogenesis occurring in a patient and the
activity of thalidomide.